Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 2015. The report serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, in accordance with DTR 3.1.4 R(1)(c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding a specific personnel transaction rather than a financial performance report.
Material Changes
The filing reports a specific increase in the notional allocation of GSK American Depositary Shares (ADSs) on June 8, 2015. This change resulted from the revaluation of the cash element of a notional investment held within the GSK 401K plan. The transaction involved Dr K Slaoui, a connected person of Dr M Slaoui, with an allocation of 5 ADSs at a price of $42.24 per ADS.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific transaction notification.
Investor Verification Points
- Verify the identity of Dr K Slaoui as a connected person of Dr M Slaoui.
- Confirm the transaction date of June 8, 2015, and the reporting date of June 9, 2015.
- Note the specific price of $42.24 per ADS used for the notional allocation revaluation.
- Understand that this filing does not contain financial performance data for the period.